EPH-like receptor protein tyrosine kinases

• US 5,981,245 A
• Filed: 05/24/1995
• Issued: 11/09/1999
• Est. Priority Date: 04/15/1994
• Status: Expired due to Fees

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Welcher, Andrew A., Jing, Shuqian, Fox, Gary M.
• Primary Examiner(s): Teng, Sally P.
• Application Number:
  US08/449,645
• Time in Patent Office: 1,630 Days
• Field of Search: 435/69.1, 435/194, 530/350, 536/23.5, 514/2
• US Class Current: 435/194
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.

Claims

1. An isolated polypeptide encoded by a nucleic acid selected from the group consisting of:

a) the nucleic acid comprising the sequence as set forth in SEQ ID NO;

16;

b) the nucleic acid comprising a sequence which hybridizes at 60°

C. in 1M Na⁺ followed by washing at 60°

C. in 0.2×

SSC to the complement of the polypeptide coding region of the nucleic acid comprising the sequence as set forth in SEQ ID NO;

16; and

c) the nucleic acid comprising a sequence which is degenerate to the nucleic acids of (a) and (b);

wherein the polypeptide comprises a mammalian EPH-like receptor protein tyrosine kinase.

6. The polypeptide of claims 1, 2 or 3 wherein the polypeptide is obtained by expression of a nucleic acid transformed or transfected into a procaryotic or eucaryotic host cell.

7. The polypeptide of claim 6 wherein the nucleic acid is cDNA.

8. The polypeptide of claim 6 wherein the nucleic acid is synthetic DNA.

9. A composition comprising a polypeptide of claims 1, 2 or 3 in a mixture with a pharmaceutically acceptable adjuvant, carrier, solubilizer or diluent.

2. An isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:

17 lacking a signal sequence.

3. An isolated polypeptide comprising a fragment of the amino acid sequence as set forth in SEQ ID NO:

17, wherein the fragment comprises an extracellular domain.

4. The polypeptide of claim 3 fused to a heterologous receptor cytoplasmic domain.

5. A polypeptide of claim 3 fused to an immunoglobulin domain.

10. A polypeptide comprising amino acids 23-553 as set forth in SEQ ID NO:

17, and optionally including an amino terminal methionyl residue.